Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose alteplase plus tirofiban versus standard-dose alteplase for non-cardioembolic acute ischemic stroke
ChiCTR1800014666Phase 2Recruiting
- Sponsor
- Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University
- Start
- Feb 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator and tirofiban in ischemic stroke (2 arms), sponsored by Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University. Primary endpoints: NIHSS score, modified Rankin Scale score and 4 more. Started Feb 2018; status: recruiting.
02
Drugs
tissue-plasminogen activatortirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1800014666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014666.